IP Library Granted Patent US 9,593,066
Granted Patent B2
US 9,593,066 · App. 14/849,981 · Granted Mar 14, 2017

Process to prepare treprostinil, the active ingredient in remodulin®

Inventors: Hitesh Batra (Herndon, VA); Sudersan M. Tuladhar (Silver Spring, MD); Raju Penmasta (Herndon, VA); David A. Walsh (Palmyra, VA)
Assignee: United Therapeutics Corporation
C07C59/72C07C51/08C07C51/41C07C51/412C07C213/08C07C405/0075A01N37/10C07C39/12C07C39/17C07C59/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,593,066
App. No.
14/849,981
Granted
Mar 14, 2017
Kind
B2
Abstract

This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.

Claims (11)

1. A pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt thereof, said composition prepared by a process comprising providing a starting batch of treprostinil having one or more impurities resulting from prior alkylation and hydrolysis steps, forming a salt of treprostinil by combining the starting batch and a base, isolating the treprostinil salt, and preparing a pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt thereof from the isolated treprostinil salt, whereby a level of one or more impurities found in the starting batch of treprostinil is lower in the pharmaceutical composition, and wherein said alkylation is alkylation of benzindene triol.

2. The pharmaceutical composition of claim 1 , wherein the salt is isolated in crystalline form.

3. The pharmaceutical composition of claim 1 , wherein the base is selected from the group consisting of sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, and choline.

4. The pharmaceutical composition of claim 3 , wherein the base is diethanolamine.

5. The pharmaceutical composition of claim 1 , wherein the base is combined with treprostinil that has not been previously isolated.

6. The pharmaceutical composition of claim 1 , wherein the isolated salt is stored at ambient temperature.

7. The pharmaceutical composition of claim 1 , which is a pharmaceutical solution.

8. A process of preparing a pharmaceutical product comprising treprostinil or a pharmaceutically acceptable salt thereof, comprising alkylating a triol intermediate of the formula:

hydrolyzing the resulting compound to form treprostinil, forming a salt of treprostinil stable at ambient temperature, storing the treprostinil salt at ambient temperature, and preparing a pharmaceutical product from the treprostinil salt after storage, wherein the pharmaceutical product comprises treprostinil or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical product prepared by the process of claim 8 .

10. The process as claimed in claim 8 , wherein forming the salt of treprostinil stable at ambient temperature is performed by adding diethanolamine to treprostinil.

Continuity (5)
Division 13933623 · Jul 2, 2013
Continuation 13548446 · Jul 13, 2012
Continuation 12334731 · Dec 15, 2008
Provisional Application 61014232 · Dec 17, 2007
Related Publication 20150376106A1 · Dec 31, 2015